Last reviewed · How we verify
L608 Liposomal inhalation suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
L608 Liposomal inhalation suspension (L608 Liposomal inhalation suspension) — Pharmosa Biopharm Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| L608 Liposomal inhalation suspension TARGET | L608 Liposomal inhalation suspension | Pharmosa Biopharm Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- L608 Liposomal inhalation suspension CI watch — RSS
- L608 Liposomal inhalation suspension CI watch — Atom
- L608 Liposomal inhalation suspension CI watch — JSON
- L608 Liposomal inhalation suspension alone — RSS
Cite this brief
Drug Landscape (2026). L608 Liposomal inhalation suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/l608-liposomal-inhalation-suspension. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab